Author: Alison McCook

Prominent NIH researcher up to a dozen retractions

Stanley Rapoport. Source: NIH

Neuroscientist Stanley Rapoport hasn’t had much luck with his co-authors.

Recently, we’ve reported on multiple retractions of papers co-authored by Rapoport after three different first authors were found to have committed misconduct. Now, the fallout from one of those cases had led to four more retractions, bringing Rapoport’s total to 12.

The latest batch of retractions stem from the actions of Jagadeesh Rao.

Here’s the first notice, issued by Psychopharmacology:

Continue reading Prominent NIH researcher up to a dozen retractions

PLOS ONE has faced a decline in submissions – why? New editor speaks

By some measures, 2016 was a somewhat rocky year for PLOS ONE — it issued some high-profile retractions, and published fewer papers, in part due to a decline in submissions. Still, the first multidisciplinary open-access journal — which accepts all submissions that meet technical and ethical standards, regardless of the results — publishes more than 20,000 papers per year, juggling thousands of editors and reviewers. So what does the future hold for this “large and complex” journal? We spoke with its new editor, Joerg Heber, who assumed the role in November.

Retraction Watch: What are your primary goals for the journal, and how do you plan to achieve them?

Continue reading PLOS ONE has faced a decline in submissions – why? New editor speaks

Journal flags another paper by diabetes researcher who sued to stop retractions

It would seem that resorting to legal means to avoid editorial notices doesn’t always work.

We’re coming to that conclusion after seeing yet another notice for Mario Saad, based at the University of Campinas in São Paulo, Brazil. In this case, it’s an expression of concern from the Journal of Endocrinology, on a 2005 paper that lists Saad as the second-to-last author. According to the notice, the journal is concerned the paper contains spliced and duplicated images; although the authors offered to repeat the experiments, the journal considered that potential delay “unacceptable.”

Despite Saad’s legal efforts, he is now up to 11 retractions, along with multiple expressions of concern.

Here’s the full text of the notice (which is paywalled, tsk tsk):

Continue reading Journal flags another paper by diabetes researcher who sued to stop retractions

Should software companies choose not to work with predatory publishers?

Jake Beal

With so many journals out there, it can be hard to know which ones are legitimate, and which ones have adopted so-called “predatory” practices – publishing anything as long as authors can pay. In this guest post, computer scientist Jacob Beal at BBN Technologies highlights one way he believes software companies may indirectly endorse questionable publishers by working with them– and why they should stop.

If you are a researcher, there’s a pretty good chance that you know Editorial Manager, the manuscript-handling system used by a vast number of journals, including Nature and the PLoS family of journals. In a publishing environment made increasingly murky by so-called “predatory” and other low-quality publishers, it used to be the case that seeing Editorial Manager was a clear signal that a journal was at least legitimate, whatever other pluses or minuses it might have.

Unfortunately, that appears to no longer be the case. Continue reading Should software companies choose not to work with predatory publishers?

“Hindsight’s a bitch:” Colleagues dissect painful retraction

Two blog posts are shining additional light on a recent retraction that included some unanswered questions — namely, the identity of the researcher who admitted to manipulating the results.

To recap: Psychological Science recently announced it was retracting a paper about the relationship between the words you use and your mood after a graduate student tampered with the results. But the sole author — William Hart, an assistant professor at the University of Alabama — was not responsible.

The post raised some questions — for instance, who was the graduate student, and if his or her work was so influential to a paper, why was he/she not listed as an author? Hart declined to identify the student, but two new blogs — including one by one of Hart’s collaborators at the University of Alabama — are providing more details.

Continue reading “Hindsight’s a bitch:” Colleagues dissect painful retraction

Pay to play? Three new ways companies are subverting academic publishing

Some recent communications from companies involved in academic publishing have some journal representatives worried. In one instance, a manuscript editing company offered to pay an editor to help its papers get published in his journal; in another, a research ethics company threatened to investigate all of an author’s papers if he or she didn’t donate thousands to support the company’s efforts. Bottom line: Research authors (and editors) should beware companies offering unethical manuscript editing and other publishing services. Below are examples (which we’ve verified) compiled by Chris Graf, Co-Vice Chair of the Committee on Publication Ethics (COPE) and Society Partnership Director at Wiley; Richard Holt, editor-in-chief of Diabetic Medicine and researcher at the University of Southampton; Tamara Welschot, the Director of Research Integrity and Publishing Services at Springer Nature; and Matt Hodgkinson, Head of Research Integrity, Hindawi Limited.

We share for the benefit of researchers (and journal editors and publishers) three new warnings cut from the same cloth as other recent peer review “scams.” These warnings appear to indicate that third parties continue to attempt to inappropriately influence peer review and journal publishing.

Here are the details.

Continue reading Pay to play? Three new ways companies are subverting academic publishing

3rd retraction appears for fired Pfizer breast cancer researcher

Pfizer has retracted a paper by a former employee who was fired after the company discovered she had been doctoring data.

The retraction, in Molecular Cancer Research, is the third of five papers Pfizer asked to retract, after an investigation discovered they contained duplicated images. The papers have been discussed on PubPeer, which is also mentioned in the latest retraction notice.

As a result of the investigation, Pfizer terminated the employment of Min-Jean Yin, the last author on the newly retracted paper.

According to the notice, Yin and five of her co-authors agreed to the retraction:

Continue reading 3rd retraction appears for fired Pfizer breast cancer researcher

Editor steps down from journal while it investigates citation irregularities

Artemi Cerdà

The editor of the journal Land Degradation & Development has stepped down amidst an investigation into citation problems at the journal.

The editor, Artemi Cerdà of the University of Valencia in Spain, has also disappeared from the list of editors at two journals published by the European Geosciences Union, which recently announced that one of its editors had engaged in citation manipulation.

Here’s a statement we just received from a spokesperson for Wiley, which publishes Land Degradation & Development:

Continue reading Editor steps down from journal while it investigates citation irregularities

“False” results in retracted paper by senator are inaccurate, not fraudulent, say editors

Daniel Biss

Last week, we wrote about a somewhat remarkable retraction, of a 15-year-old paper by a current Illinois senator who used to be a mathematician. At the time, we were a bit perplexed by the language of the notice, which the senator — who helpfully took our call — couldn’t answer, since he wasn’t involved in drafting the notice.

We’ve since heard back from the journal that retracted the paper, which explained that their phrase that “most results are false” meant the findings by state senator Daniel Biss were inaccurate — not fraudulent.

Here’s more explanation from a joint statement sent to us by Jan van Mill and Jerry Vaughan, the editors in chief of Topology and its Applications:

Continue reading “False” results in retracted paper by senator are inaccurate, not fraudulent, say editors

Researcher loses biotech post after reportedly confessing to fraud

A researcher has lost his position as a Chief Scientific Officer at a DNA sequencing company after he reportedly confessed to fabricating data in a 2015 paper, now retracted by the Journal of Cell Biology.

According to the CEO of Karmagenes, when the company learned about the retraction, the staff “immediately” conferred and decided the researcher — Pranav Ullal — should no longer serve as one of the company’s two CSOs.

Karmagenes CEO Kyriakos Kokkoris told us:

Continue reading Researcher loses biotech post after reportedly confessing to fraud